The global pain management drugs market size was evaluated at USD 84.1 billion in 2024 and is expected to grow around USD 126.9 billion by 2034, registering a CAGR of 4.2% from 2025 to 2034.
| Industry Worth | Details |
| Market Size in 2025 | USD 87.63 Billion |
| Market Size by 2034 | USD 126.9 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 4.2% |
The pain management drugs market is defined as the market for medicinal use to mitigate or handle pain. It involves numerous types of drugs intended to treat distinctive levels and various types of pain, extending from acute to chronic pain. This is described by dynamic reasons guided by both medical developments and socio-economic trends. This demographic shift entails effective pain management solutions, driving research and development in the market. Technological developments in drug delivery systems and formulations have accelerated treatment alternatives, improving efficacy and patient compliance. The shift towards customized medicine further impels innovation, modifying treatments to individual patient demands based on physiological, genetic, and lifestyle factors.
"We're proud to provide affordable choices to healthcare providers and their appropriate patients while strengthening our reputation as a reliable, quality supplier," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo.
"The FDA approval of Aimovig demonstrates Novartis' commitment to bringing meaningful new medicines to patients with complex neurologic diseases, like migraine," said Paul Hudson, CEO of Novartis Pharmaceuticals. "Aimovig is the first therapy of its kind targeting the CGRP receptor and has demonstrated robust efficacy across the spectrum of migraine. We look forward to working closely with Amgen in the U.S. to bring this treatment to physicians and their patients, who could now gain days of their lives back each month."
The pain management drugs market is experiencing significant growth, with North America maintaining its position as the dominant region while Europe emerges as the rapidly growing market. The Asia Pacific region is projected to be the fastest-growing in the market during the forecast period.
North America
North America dominated the global pain management drugs market in 2024. This is attributed to the high incidence of chronic pain conditions, progressive healthcare infrastructure, and the existence of major pharmaceutical firms engaged in pain management drug development. However, the increasing rate of surgical processes requiring post-operative pain management is positively affecting the market expansion.
Europe
Europe is experiencing rapid growth in the pain management drugs market during the forecast period. The significant healthcare spending, robust healthcare systems, and a well-known pharmaceutical industry in the region are promoting market growth. Besides this, the increasing focus on safe and efficient pain management therapies, along with rising awareness about pain management amongst healthcare providers and patients, is leading to the market growth.
APAC
Asia Pacific (APAC) is projected to be the fastest-growing in the market during the forecast period. It is boosted by the rising prevalence of chronic disorders, enhancing healthcare infrastructure, and growing healthcare expenditures. Thus, the rising geriatric population in the region who are subjective to chronic pain conditions is boosting the market expansion. Meanwhile, the accelerating pharmaceutical industry and rising access to healthcare services are boosting market expansion.
Across the acute pain market, several contributing firms are at the leading edge of advancing integrated platforms to improve the management of acute pain. Some of the key players include Janssen and Assertio Therapeutics. These firms are boosting innovation in the acute pain market via diagnostic tools, continuous research, and accelerating their product provision to meet the increasing need for illness.
Teva Pharmaceutical Industries Ltd. was one of the first firms to offer generic drugs, and now it is one of the largest pharmaceutical firms in the world, with 16,000 products related to novel drugs, generics, and over-the-counter medications. It had been active in supplying drugs to 200 million people globally and 60 countries internationally.
Pfizer functions in a highly competitive and highly regulated market. The pharmaceutical industry needs significant take-up on research and development. Pfizer’s main competitors include Merck & Co. Inc. (MRK), Eli Lilly & Co. (LLY), Switzerland-derived Novartis AG (NVS), Johnson & Johnson, and Bristol-Myers Squibb Co. (BMY).
Abbott Laboratories is a public firm headquartered in Illinois with an estimated 115,000 employees, where they account for an estimated 58.6% of total industry revenue and are considered an All-Star because they show stronger market profit, share, and revenue expansion compared to their peers.
Annual Revenue: Teva Pharmaceutical Industries Limited vs Pfizer Inc. vs Abbott Laboratories 2022-24 (Millions of US$)
| Year | Teva Pharmaceutical Industries Limited | Pfizer Inc. | Abbott Laboratories |
| 2024 | 16,544,000 | 63,627,000 | 41,950,000 |
| 2023 | 15,845,000 | 59,553,000 | 40,109,000 |
| 2022 | 14,925,000 | 101,175,000 | 43,653,000 |
Published by Deepa Pandey
